The current Phase 2b study (MORF-057-202) aims to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 (as capsule, by mouth [P.O.]) versus placebo in study participants with moderately to severely active UC. Data from this study will provide further information to advance the clinical development program of MORF-057 for the treatment of UC.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Hans Herfarth
Center for Gastrointestinal Biology and Disease
Clinical or Medical
Interventional
Stomach, Digestion and Gut Health
22-2488
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
